Loading...
Market
Story
Genentech Acquires Regor's CDK Inhibitors in Definitive Purchase Agreement for $850 Million
Sep 30, 2024, 08:46 AM
Genentech has announced the acquisition of Regor's portfolio of next-generation CDK inhibitors for $850 million upfront, with potential for additional milestone payments. The definitive purchase agreement aims to enhance Genentech's capabilities in the treatment of breast cancer.
View original story
Similar markets
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $100M • 25%
$100M - $500M • 25%
$500M - $1B • 25%
More than $1B • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Below $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
Above $300 million • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%